findmyKOL
Clinical trialNCT03217734CompletedPhase 2/PHASE3Interventional

MAP Study: Methotrexate and Adalimumab in Psoriasis

SponsorJeffrey J Crowley MDEnrollment56Psoriasis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jeffrey J Crowley, MD

    Bakersfield Dermatology and Skin Cancer Medical Group

    Study Director

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Bakersfield Dermatology and Skin Cancer Medical Group

    Bakersfield, California, United States

  • Clinical Science Institute

    Santa Monica, California, United States

  • Dermassociates, Pc

    Rockville, Maryland, United States

  • Modern Research Associates, Pllc

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Apr 2017
Primary completion
31 Dec 2018
Completion
31 Dec 2018
Last update posted
9 Jul 2019
Registered enrollment
56
Registry id
NCT03217734

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.